Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis

R. Costa*, N. Gill, A. W. Rademaker, B. A. Carneiro, Y. K. Chae, P. Kumthekar, W. J. Gradishar, R. Kurzrock, F. J. Giles

*Corresponding author for this work

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Purpose This systematic review aims to better define the limitations and patterns with which patients with MBC and CNS metastasis are enrolled into early phase developmental therapeutics trials. Methods In June 2016, PubMed search was conducted using the following keywords: “Breast cancer”. Drug-development phase 1, phase 2 or phase 1/2 trials for patients with MBC were included. Multiple-histology trials and trials without an efficacy endpoint were excluded. Results In total, 1474 studies were included; Inclusion criteria for 423 (29%) allowed for CNS metastasis, 770 (52%) either excluded or did not document eligibility of patients with CNS disease. Trials accruing patients with HER2-positive MBC and including targeted therapies had higher odds of allowing for patients with CNS disease (adjusted OR 1.56, 95% CI 1.08–2.2.6; p = 0.019 and 1.49, 95% 1.08–2.06; p = 0.014, respectively). There were also higher odds of accrual of patients with CNS involvement into clinical trials over time (odds ratio = 1.10, 95% CI 1.07–1.12; p < 0.0001). Conclusion Most published early phase clinical trials either did not clearly document or did not allow for accrual of patients with CNS disease. Early phase trials with targeted agents or enrolling HER2+ MBC had higher odds of permitting CNS metastases.

Original languageEnglish (US)
Pages (from-to)10-15
Number of pages6
JournalCancer Treatment Reviews
Volume55
DOIs
StatePublished - Apr 1 2017

Keywords

  • Brain metastasis
  • Breast cancer
  • Early phase clinical trials

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis'. Together they form a unique fingerprint.

  • Cite this